Brief: Organogenesis Q3 Revenue USD 108.5 Million
09/11/2023 21:05
Nov 09 (Reuters) - Organogenesis Q3 adjusted net income USD 5.3 million. * Q3 operating income USD 8.1 million * Q3 net income USD 3.2 million * Q3 adjusted EBITDA USD 16 million * outlook FY net income USD 4-9 million * outlook FY adjusted net income USD 11-17 million * outlook FY adjusted EBITDA USD 40-51 million * outlook FY EBITDA USD 26-37 million
Recent news on Organogenesis Holdings
See all newsBrief: Organogenesis Announces Publication Of Peer-Reviewed Prepare Trial Results
Organogenesis Holdings Inc. reports results for the quarter ended June 30 - Earnings Summary
Brief: Organogenesis Q2 Net Product Revenue USD 42.8 Million
Organogenesis Holdings Inc. expected to post a loss of 35 cents a share - Earnings Preview
Brief: Organogenesis Announces Publication Of Peer-Reviewed Clinical Trial Results Demonstrating Clinical Benefit Of Affinity™ In The Most Challenging And Complex Venous Leg Ulcers